Table 1—

Characteristics of study subjects by initial stage of IFG

Added IFG subjects (100–109 mg/dl)Original IFG subjects (110–125 mg/dl)P value
n (%)4,526 (83.0)926 (17.0)
Months of follow-up*75.6 (34.1)68.2 (35.2)<0.0001
Age at IFG incidence (years)59.7 (11.1)57.9 (11.6)<0.0001
Female (%)48.153.90.001
FPG
    Prior to IFG incidence93.8 (4.8)93.5 (5.4)0.119
    Incident measure103.5 (2.8)115.4 (4.4)<0.0001
    Months between pre- and incident FPG17.8 (15.7)22.5 (18.8)<0.0001
Current smoker (%)22.124.00.206
Comorbidities (%)
    History of myocardial infarction9.18.40.524
    History of stroke9.28.60.595
    Other ASCVD21.518.60.045
    Congestive heart failure7.510.60.002
    History of depression24.030.6<0.0001
Systolic blood pressure (mmHg)134 (13)136 (13)0.017
Diastolic blood pressure (mmHg)79 (7)80 (7)0.033
BMI (kg/m2)31.0 (6.3)33.2 (7.2)<0.0001
HDL cholesterol (mg/dl)51 (15)48 (14)<0.0001
Triglycerides (mg/dl)190 (215)212 (138)0.004
LDL cholesterol (mg/dl)126 (30)121 (31)<0.0001
  • Data are means (SD) or percent.

  • *

    * Follow-up was terminated at the earlier stage of progression to diabetes (11.3%), at health plan termination (19.1%), at death (6.4%), or on 31 December 2005 (63.2%). ASCVD, atherosclerotic cardiovascular disease.